congresses-banner
The content contained is subject
The content contained is subject to congress/journal copyright permissions. No further reproduction is permitted without permission of the copyright owner.
Information about pipeline compounds or investigational uses of compounds does not imply FDA approval for these compounds or uses, nor does it establish the safety or efficacy of these compounds or uses. There is no guarantee that the pipeline compounds or investigational uses will receive FDA approval. Daiichi Sankyo does not recommend or suggest use of its medicines in a manner inconsistent with FDA-approved labeling.
congresses-tab
PublicationView
Poster
T-DXd
Miami Breast 2024 | March 7-10, 2024
Addressing barriers to identifying HER2-low metastatic breast cancer patients in a large
community oncology practice
Poster
Dato-DXd
Miami Breast 2024 | March 7-10, 2024
Datopotamab deruxtecan (Dato-DXd) vs chemotherapy in
previously-treated inoperable or metastatic hormone receptor-positive,
HER2-negative (HR+/HER2–) breast cancer: Primary results from the
randomized phase 3 TROPION-Breast01 trial
Poster
Other/Multi
Miami Breast 2024 | March 7-10, 2024
Racial disparities in treatment patterns and outcomes among HER2-low metastatic breast cancer patients treated in US community oncology practices
Poster
Other/Multi
Miami Breast 2024 | March 7-10, 2024
Treatment patterns and clinical outcomes following endocrine resistance among HER2-low metastatic breast cancer patients – retrospective observational study
Poster
Dato-DXd
Miami Breast 2024 | March 7-10, 2024
TROPION-Breast05: A phase 3 study of datopotamab deruxtecan (Dato-DXd) with or without durvalumab versus chemotherapy plus
pembrolizumab in patients with PD-L1 positive locally recurrent inoperable or metastatic triple-negative breast cancer